Spun out of the Columbia Labs of one of the founders and the Labs at UC San Diego of another Founder, GenCirq, Inc. is developing a novel class of bacterial therapeutics with the latest advances in Synthetic Biology. The firm's personnel define the firm's intent as being the disruption and expansion of the living therapy and oncology markets with the firm's proprietary synchronized lysis circuit (SLC) technology, Synchronized Lysis Circuit (SLC) supports controlled delivery of therapeutics and enhances the safety of bacterial cancer therapy. Enabling the safe and effective delivery of a broad range of therapeutics to solid tumors, the platform technology leverages recent advances in synthetic biology to program probiotic bacteria safely and specifically to colonize tumors. Colonization achieved, the bacteria produce and release anti-cancer agents (chemotoxins, immunotherapeutic nanobodies, cytokines etc.) locally within the tumor. This process of local production and delivery at disease sites serves to mitigate sthe ystemic side effects of many conventional therapeutics. It is reproted that preclinical data in multiple mouse models have demonstrated the modularity and robustness of the platform to function in diverse conditions and therapeutic contexts.
